Thomas Fitzgerald
Vermögen: 14 $ am 31.07.2026
Vermögen: 14 $ am 31.07.2026
Thomas A. Fitzgerald is Chief Financial Officer, Secretary, Director & VP at TransCode Therapeutics, Inc. since 2025.
Formerly, Mr. Fitzgerald was MD-Corporate Finance & Investment Banking Unit at Leerink Partners LLC and Chief Financial Officer at Velico Medical, Inc. from 2006 to 2018.
Education includes undergraduate studies at Stanford University and an MBA from Harvard Business School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 28.05.2026 | 3 ( 0 % ) | 14 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| TRANSCODE THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.07.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
Velico Medical, Inc.
Velico Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Offers proprietary technologies for blood transfusion | Finanzdirektor/CFO | 01.12.2018 |
Leerink Partners LLC
Leerink Partners LLC Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Leerink Partners LLC
Leerink Partners LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Velico Medical, Inc.
Velico Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Offers proprietary technologies for blood transfusion | Electronic Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes diagnostics and therapeutics for the detection and treatment of cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen